Literature DB >> 29976759

High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation.

Preetha Shridas1,2, Maria C De Beer2,3,4, Nancy R Webb2,4,5.   

Abstract

Serum amyloid A (SAA) is a high-density apolipoprotein whose plasma levels can increase more than 1000-fold during a severe acute-phase inflammatory response and are more modestly elevated in chronic inflammation. SAA is thought to play important roles in innate immunity, but its biological activities have not been completely delineated. We previously reported that SAA deficiency protects mice from developing abdominal aortic aneurysms (AAAs) induced by chronic angiotensin II (AngII) infusion. Here, we report that SAA is required for AngII-induced increases in interleukin-1β (IL-1β), a potent proinflammatory cytokine that is tightly controlled by the Nod-like receptor protein 3 (NLRP3) inflammasome and caspase-1 and has been implicated in both human and mouse AAAs. We determined that purified SAA stimulates IL-1β secretion in murine J774 and bone marrow-derived macrophages through a mechanism that depends on NLRP3 expression and caspase-1 activity, but is independent of P2X7 nucleotide receptor (P2X7R) activation. Inhibiting reactive oxygen species (ROS) by N-acetyl-l-cysteine or mito-TEMPO and inhibiting activation of cathepsin B by CA-074 blocked SAA-mediated inflammasome activation and IL-1β secretion. Moreover, inhibiting cellular potassium efflux with glyburide or increasing extracellular potassium also significantly reduced SAA-mediated IL-1β secretion. Of note, incorporating SAA into high-density lipoprotein (HDL) prior to its use in cell treatments completely abolished its ability to stimulate ROS generation and inflammasome activation. These results provide detailed insights into SAA-mediated IL-1β production and highlight HDL's role in regulating SAA's proinflammatory effects.
© 2018 Shridas et al.

Entities:  

Keywords:  NLRP3; Serum Amyloid A; high-density lipoprotein (HDL); inflammasome; interleukin 1 (IL-1); reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2018        PMID: 29976759      PMCID: PMC6109913          DOI: 10.1074/jbc.RA118.002428

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

Review 1.  Regulation of inflammasome activation.

Authors:  Si Ming Man; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

2.  Is the serum amyloid A we use really serum amyloid A? Comment on the article by Connolly et al.

Authors:  Ben van den Brand; Claire Waterborg; Wim van den Berg; Fons van de Loo
Journal:  Arthritis Rheum       Date:  2013-01

3.  Serum amyloid A induces reactive oxygen species (ROS) production and proliferation of fibroblast.

Authors:  E Hatanaka; A Dermargos; H A Armelin; R Curi; A Campa
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

4.  SAA does not induce cytokine production in physiological conditions.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Nancy R Webb; Frederick C de Beer
Journal:  Cytokine       Date:  2012-11-17       Impact factor: 3.861

5.  Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors.

Authors:  P A Amstad; G Yu; G L Johnson; B W Lee; S Dhawan; D J Phelps
Journal:  Biotechniques       Date:  2001-09       Impact factor: 1.993

6.  Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

Review 7.  NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?

Authors:  Jurg Tschopp; Kate Schroder
Journal:  Nat Rev Immunol       Date:  2010-02-19       Impact factor: 53.106

8.  Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation.

Authors:  William F Johnston; Morgan Salmon; Gang Su; Guanyi Lu; Matthew L Stone; Yunge Zhao; Gary K Owens; Gilbert R Upchurch; Gorav Ailawadi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

9.  Is serum amyloid A an endogenous TLR4 agonist?

Authors:  Silvana Sandri; Dunia Rodriguez; Eliane Gomes; Hugo Pequeno Monteiro; Momtchilo Russo; Ana Campa
Journal:  J Leukoc Biol       Date:  2008-02-05       Impact factor: 4.962

10.  ATP release and purinergic signaling in NLRP3 inflammasome activation.

Authors:  Aurélie Gombault; Ludivine Baron; Isabelle Couillin
Journal:  Front Immunol       Date:  2013-01-08       Impact factor: 7.561

View more
  24 in total

Review 1.  Role of serum amyloid A in atherosclerosis.

Authors:  Preetha Shridas; Lisa R Tannock
Journal:  Curr Opin Lipidol       Date:  2019-08       Impact factor: 4.776

2.  Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.

Authors:  Jin Yu; Hong Zhu; Saeid Taheri; William Mondy; Leonardo Bonilha; Gayenell S Magwood; Daniel Lackland; Robert J Adams; Mark S Kindy
Journal:  J Neurosci       Date:  2019-10-14       Impact factor: 6.167

3.  Serum amyloid A is not incorporated into HDL during HDL biogenesis.

Authors:  Ailing Ji; Xuebing Wang; Victoria P Noffsinger; Drew Jennings; Maria C de Beer; Frederick C de Beer; Lisa R Tannock; Nancy R Webb
Journal:  J Lipid Res       Date:  2020-01-08       Impact factor: 5.922

4.  DNA Damage Promotes Epithelial Hyperplasia and Fate Mis-specification via Fibroblast Inflammasome Activation.

Authors:  Lindsey Seldin; Ian G Macara
Journal:  Dev Cell       Date:  2020-10-14       Impact factor: 12.270

5.  Serum Amyloid A Contributes to Chronic Apical Periodontitis via TLR2 and TLR4.

Authors:  K Hirai; H Furusho; N Kawashima; S Xu; M C de Beer; R Battaglino; T Van Dyke; P Stashenko; H Sasaki
Journal:  J Dent Res       Date:  2018-09-06       Impact factor: 6.116

6.  Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.

Authors:  Ulrich Laufs; Thimoteus Speer; Stephen Zewinger; Jochen Reiser; Vera Jankowski; Dalia Alansary; Eunsil Hahm; Sarah Triem; Mira Klug; Stefan J Schunk; David Schmit; Rafael Kramann; Christina Körbel; Emmanuel Ampofo; Matthias W Laschke; Simina-Ramona Selejan; Anna Paschen; Tobias Herter; Susanne Schuster; Günther Silbernagel; Martina Sester; Urban Sester; Gunter Aßmann; Robert Bals; Gerhard Kostner; Willi Jahnen-Dechent; Michael D Menger; Lucia Rohrer; Winfried März; Michael Böhm; Joachim Jankowski; Manfred Kopf; Eicke Latz; Barbara A Niemeyer; Danilo Fliser
Journal:  Nat Immunol       Date:  2019-12-09       Impact factor: 25.606

7.  Native and oxidised lipoproteins negatively regulate the serum amyloid A-induced NLRP3 inflammasome activation in human macrophages.

Authors:  Katariina Nurmi; Katri Niemi; Ilona Kareinen; Kristiina Silventoinen; Martina B Lorey; Yan Chen; Vesa-Petteri Kouri; Jukka Parantainen; Timo Juutilainen; Katariina Öörni; Petri T Kovanen; Dan Nordström; Sampsa Matikainen; Kari K Eklund
Journal:  Clin Transl Immunology       Date:  2021-08-03

8.  Sexually Dimorphic Relationships Among Saa3 (Serum Amyloid A3), Inflammation, and Cholesterol Metabolism Modulate Atherosclerosis in Mice.

Authors:  Alan Chait; Shari Wang; Leela Goodspeed; Diego Gomes; Katherine E Turk; Tomasz Wietecha; Jingjing Tang; Carl Storey; Kevin D O'Brien; Katya B Rubinow; Chongren Tang; Tomas Vaisar; Sina A Gharib; Aldons J Lusis; Laura J Den Hartigh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-25       Impact factor: 10.514

9.  Serum Amyloid A is not obligatory for high-fat, high-sucrose, cholesterol-fed diet-induced obesity and its metabolic and inflammatory complications.

Authors:  Ailing Ji; Andrea C Trumbauer; Victoria P Noffsinger; Hayce Jeon; Avery C Patrick; Frederick C De Beer; Nancy R Webb; Lisa R Tannock; Preetha Shridas
Journal:  PLoS One       Date:  2022-04-18       Impact factor: 3.752

10.  High-Density Lipoprotein from Chronic Kidney Disease Patients Modulates Polymorphonuclear Leukocytes.

Authors:  Jana Raupachova; Chantal Kopecky; Gerald Cohen
Journal:  Toxins (Basel)       Date:  2019-02-01       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.